By Canadian Press

Feds recover $40M from defunct Quebec vaccine developer Medicago

Dec 8, 2023 | 10:27 AM

OTTAWA — The federal government says it has recovered $40 million from the now-defunct Quebec-based vaccine developer Medicago, and the intellectual property will remain in Canada under a new firm.

The government provided Medicago a $173-million advance in the early days of the COVID-19 pandemic to develop and produce a plant-based vaccine in Quebec City.

The company’s Japanese parent company, Mitsubishi Chemical Group, shut down Medicago’s operations in February as global demand for vaccinations plummeted.

Though Medicago’s vaccine was approved for use in Canada, it was not approved by the World Health Organization due to the company’s ties with tobacco giant Philip Morris.

The agreement between Canada and Mitsubishi Chemical Group will transfer the research, intellectual property and equipment to a new operation: Aramis Biotechnologies.

1000 Ways to Heal

1000 Ways to Heal: Moons

Dec 10, 2024

Question of the Week

Should Mayor Reid Hamer-Jackson apologize or resign after it was found he breached a section of council's code of conduct for allowing false or misleading information to be communicated?

Dec 09, 2024

One Man's Opinion

COLLINS: Donald has it wrong - again

Dec 08, 2024

Aramis Biotechnologies is also based in Quebec City and is led by former Medicago employees.

This report by The Canadian Press was first published Dec. 8, 2023.

The Canadian Press